[Granulocyte colony-stimulating factor in the newborn neutropenic patient].
OBJECTIVE
To assess the therapeutic effect of G-CSF in newborns with neutropenia.


METHODS
Newborn with evidence of both peripheral neutropenia and decreased granulocytic precursors in tibial bone marrow aspirate were included in the study. G-CSF was perfused intravenously over 2 hours at dose of 10 micrograms/kg/day, during 4-8 days. CBC were obtained immediately before each dose of G-CSF.


RESULTS
Neutropenia followed neonatal sepsis in four cases and maternal pre-eclampsia in three. Prior to treatment, peripheral blood granulocyte (PMNL) counts ranged from 420 to 1,073/mm3. Once G-CSF infusion was started, counts returned to normal within 24-48 hours. No adverse effects related to G-CSF administration were noticed.


CONCLUSIONS
G-CSF induces a significant increase in peripheral PMNL counts in newborn with neutropenia, in the absence of significant toxic effects. Our date suggest a potential role for G-CSF in the prophylaxis and treatment of sepsis in the neutropenic newborn, although widespread recommendation must await further, controlled studies.
Castillo Salinas
F
F
Servicio de Neonatología, Hospital Universitario Materno-Infantil Valle Hebrón, Barcelona.
Díaz de Heredia Rubio
C
C
Salcedo Abizanda
S
S
Ferrer Comalat
A
A
Bastida Vila
P
P
Ortega Aramburu
J J
JJ
Peguero Monforte
G
G
D003131:Combined Modality Therapy; D004341:Drug Evaluation; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007231:Infant, Newborn; D007262:Infusions, Intravenous; D007958:Leukocyte Count / Q000187:drug effects; D009503:Neutropenia / Q000097:blood / Q000188:drug therapy*; D009504:Neutrophils / Q000166:cytology / Q000187:drug effects; D011994:Recombinant Proteins; D013997:Time Factors